In-Office BPH Therapies are non-surgical treatment options that are performed in the urologist’s office generally in less than one hour. These procedures do not require general anesthesia and allow the patient to return home after the procedure has been performed. Research has proven that minimally invasive treatments are a safe, effective and durable option for BPH with very few side effects.1,2 These therapies are ideal for patients who do not want to take daily medications for the rest of their lives, dislike the side effects and ongoing costs of medication or do not want the risks, side effects or high costs of invasive surgery. The most common in-office BPH therapies are Transurethral Microwave Thermotherapy (TUMT) and Transurethral Needle Ablation (TUNA).
As with any medical procedure, there are potential risks and side effects that can occur with in-office medical procedures. We’re committed to providing you with the information you need to make a well-informed decision about your treatment options. Although these problems rarely occur, we want you to know the facts. Please refer to the Cooled ThermoTherapy™ and Prostiva® RF Therapy sections to learn about the benefits and risks specifically associated with these procedures.
If you’re considering an in-office procedure, we encourage you to watch our online educational seminar. You’ll learn about Benign Prostate Hyperplasia (BPH), BPH treatment options, and the benefits and risks of each of the treatment alternatives. You will also hear more about in-office BPH therapies such as Cooled ThermoTherapy™ and Prostiva® RF Therapy.
Watch our Patient Education Seminar here.
1Mynderse LA, Roehrborn CG, et al. Results of a 5-Year Multicenter Trial of a New Generation Cooled High Energy Transurethral Microwave Thermal Therapy Catheter for Benign Prostatic Hyperplasia. Journal of Urology. Vol. 185, 1804-1811, May 2011 2Hill, B., et al Transurethreal Needle Ablation vs TURP for the Treatment of Symptomatic BPH: 5 Year Results of a Prospective, Randomized, Multicenter Clinical Trial, Journal of Urology Vol 171, 2336-2340, June 2004 3Data derived from the CTC Advance® Instructions for Use, 250348 Rev D 08/10 4Data derived from Proscar Labeling 9631304 www.fda.gov